COCOON Baseline Characteristics
Panelists discuss how the baseline characteristics of patients in the COCOON trial were evenly matched, with slightly more women than men and a significant number of Asian patients, which is typical for EGFR-mutant non–small cell lung cancer.
EP: 1.Clinical Insights: Experiences With Amivantamab-Lazertinib in EGFR-Mutant NSCLC
EP: 2.Overview of Study Design of the COCOON Trial
EP: 3.COCOON Baseline Characteristics
EP: 4.COCOON: Discussion of Clinical End Points and Dose Modifications
EP: 5.Initial Reactions to COCOON Study’s Dermatologic/Nail AE Reductions
EP: 6.Clinician Experiences: COCOON Regimen vs Traditional SoC AE Management
EP: 7.Measuring Impact: Observed Differences in Dermatologic AEs Between COCOON Protocol and Standard Approaches
EP: 8.Building Support Systems: Resources and Multidisciplinary Collaboration for Optimizing COCOON Implementation
EP: 9.Operational Considerations: Workflow Adjustments and Monitoring Systems for Effective COCOON Implementation
EP: 10.COCOON in Practice: Patient Preparation, Key Insights, and Implementation Best Practices
Video content above is prompted by the following:
Baseline Characteristics of COCOON Study Population
Upon reviewing the baseline characteristics of the study population, both arms appear to be well-balanced overall, with no significant disparities that would affect the interpretation of treatment outcomes.
- The demographic distribution reflects a slightly higher proportion of female patients than male patients, which is consistent with the known epidemiology of EGFR-mutant non–small cell lung cancer (NSCLC). This subtype of lung cancer is more frequently observed in women.
- The average age of participants is in the early 60s, aligning with the typical age of diagnosis for EGFR-mutant NSCLC. Additionally, there is a notably high representation of Asian patients, which is expected given the increased prevalence of EGFR mutations among individuals of Asian descent, including both Asian Americans and those residing in Asia.
Overall, the baseline characteristics were consistent with what would be expected in a population with EGFR-mutant NSCLC and there were no surprising findings that would confound or bias the study’s comparative analysis between the treatment arms.
